These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 25341681)

  • 1. Quality of life and time to death: have the health gains of preventive interventions been underestimated?
    Gheorghe M; Brouwer WB; van Baal PH
    Med Decis Making; 2015 Apr; 35(3):316-27. PubMed ID: 25341681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating Quality of Life Decrements in Oncology Using Time to Death.
    Versteegh M; van der Helm I; Mokri H; Oerlemans S; Blommestein H; van Baal P
    Value Health; 2022 Oct; 25(10):1673-1677. PubMed ID: 35803844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Burden of Diabetes Mellitus in Patients with Coronary Heart Disease: A Methodological Approach to Assess Quality-Adjusted Life-Years Based on Individual-Level Longitudinal Survey Data.
    Laxy M; Hunger M; Stark R; Meisinger C; Kirchberger I; Heier M; von Scheidt W; Holle R
    Value Health; 2015 Dec; 18(8):969-76. PubMed ID: 26686780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Willingness to pay for quality and length of life gains in end of life patients of different ages.
    Reckers-Droog V; van Exel J; Brouwer W
    Soc Sci Med; 2021 Jun; 279():113987. PubMed ID: 33975052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which is more valuable, longer survival or better quality of life? Israeli oncologists' and family physicians' attitudes toward the relative value of new cancer and congestive heart failure interventions.
    Greenberg D; Hammerman A; Vinker S; Shani A; Yermiahu Y; Neumann PJ
    Value Health; 2013; 16(5):842-7. PubMed ID: 23947979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study.
    Feenstra TL; Hamberg-van Reenen HH; Hoogenveen RT; Rutten-van Mölken MP
    Value Health; 2005; 8(3):178-90. PubMed ID: 15877590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
    Pradelli L; Iannazzo S; Zaniolo O
    Am J Cardiovasc Drugs; 2009; 9(6):383-92. PubMed ID: 19929036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the relative value of end of life QALYs: Are the comparators important?
    McHugh N; Pinto-Prades JL; Baker R; Mason H; Donaldson C
    Soc Sci Med; 2020 Jan; 245():112660. PubMed ID: 31765855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The burden of stroke in the Netherlands: estimating quality of life and costs for 1 year poststroke.
    van Eeden M; van Heugten C; van Mastrigt GA; van Mierlo M; Visser-Meily JM; Evers SM
    BMJ Open; 2015 Nov; 5(11):e008220. PubMed ID: 26614618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term survival, quality of life, and quality-adjusted life-years among critically ill elderly patients.
    Kaarlola A; Tallgren M; Pettilä V
    Crit Care Med; 2006 Aug; 34(8):2120-6. PubMed ID: 16763517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A welfare economic approach to measure outcomes in stuttering: comparing willingness to pay and quality adjusted life years.
    Franic DM; Bothe AK; Bramlett RE
    J Fluency Disord; 2012 Dec; 37(4):300-13. PubMed ID: 23218213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Italian population-based values of EQ-5D health states.
    Scalone L; Cortesi PA; Ciampichini R; Belisari A; D'Angiolella LS; Cesana G; Mantovani LG
    Value Health; 2013; 16(5):814-22. PubMed ID: 23947975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Load Model: an alternative to QALY.
    Benson T
    J Med Econ; 2017 Feb; 20(2):107-113. PubMed ID: 27559918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.
    van Boven JF; Kocks JW; Postma MJ
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2191-2201. PubMed ID: 27703341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Community or patient preferences for cost-effectiveness of cardiac rehabilitation: does it matter?
    Oldridge N; Furlong W; Perkins A; Feeny D; Torrance GW
    Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):608-15. PubMed ID: 18800005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life in psoriasis: an analysis of Psocare project patients.
    Spandonaro F; Altomare G; Berardesca E; Calzavara-Pinton P; Chimenti S; Girolomoni G; Peserico A; Guerra AP; Vena GA; Polistena B; Ayala F
    G Ital Dermatol Venereol; 2011 Jun; 146(3):169-77. PubMed ID: 21566546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The cost per year of life gained: trends and internal contradictions].
    Smulders YM; Thijs A
    Ned Tijdschr Geneeskd; 2006 Nov; 150(45):2467-70. PubMed ID: 17137090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Disease Management Programs for Cardiovascular Risk and COPD in The Netherlands.
    Tsiachristas A; Burgers L; Rutten-van Mölken MP
    Value Health; 2015 Dec; 18(8):977-86. PubMed ID: 26686781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life: an outcomes perspective.
    Kaplan RM
    Arch Phys Med Rehabil; 2002 Dec; 83(12 Suppl 2):S44-50. PubMed ID: 12474171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.